(FAMOTIDINE) INJECTION PREMIXED
The active ingredient in PEPCID (Famotidine) Injection Premixed and PEPCID (famotidine) Injection is a histamine H2-receptor antagonist.
PEPCID Injection Premixed, supplied as a premixed solution in plastic containers (PL 2501 Plastic), and PEPCID Injection, supplied as a concentrated solution for intravenous injection, are intended for intravenous use only. PEPCID Injection Premixed and PEPCID Injection are indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions:
Short term treatment of active duodenal ulcer.
Most adult patients heal within 4 weeks; there is rarely reason to use PEPCID at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks.
Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
Controlled studies in adults have not extended beyond one year.
Short term treatment of active benign gastric ulcer.
Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.
Short term treatment of gastroesophageal reflux disease (GERD).
PEPCID is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS,
PEPCID is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS,
Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)
(see CLINICAL PHARMACOLOGY IN ADULTS,
Published Studies Related to Pepcid Injection (Famotidine)
Esomeprazole Compared With Famotidine in the Prevention of Upper Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome or Myocardial Infarction. [2011.11.22]
CONCLUSIONS:In patients with ACS or STEMI, esomeprazole is superior to famotidine in preventing upper gastrointestinal complications related to aspirin, clopidogrel, and enoxaparin or thrombolytics.Am J Gastroenterol advance online publication, 22 November 2011; doi:10.1038/ajg.2011.385.
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. [2011.07]
The preventive effects of lansoprazole and famotidine on low-dose aspirin-induced gastric mucosal injury in relation to gastric acidity were compared in healthy Japanese volunteers. Fifteen Helicobacter pylori-negative volunteers with different CYP2C19 genotypes were randomly administered aspirin 100 mg, aspirin plus famotidine 20 mg twice daily, or aspirin plus lansoprazole 15 mg once daily for 7 days each in a crossover fashion.
Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. [2011.03]
OBJECTIVE: Helicobacter pylori eradication therapy alone cannot heal gastric ulcers in Japanese patients. Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H. pylori eradication therapy. And we previously reported that histamine H(2) receptor antagonists inhibit gastric ulcer relapse after H. pylori eradication therapy. We therefore compared the efficacy of irsogladine with famotidine as appropriate treatments for ulcers after eradication therapy... CONCLUSIONS: Irsogladine and famotidine are both acceptable in treatment after H. pylori eradication therapy in gastric ulcer patients. Findings also suggest that irsogladine is more beneficial than famotidine in patients who drink alcohol and smoke.
Efficacy of oral famotidine and 2 omeprazole formulations for the control of intragastric pH in dogs. [2011.01]
BACKGROUND: Little is known about the efficacy of commonly used acid suppressants on intragastric pH in dogs. OBJECTIVE: To compare the effect of oral famotidine, 2 formulations of omeprazole, and placebo on intragastric pH in dogs with a catheter-free, continuous pH monitoring system. ANIMALS: Six healthy adult mixed-breed colony dogs... CONCLUSION: Oral omeprazole tablet and RP provide superior gastric acid suppression to famotidine, and should therefore be considered more effective for the treatment of acid related disorders in dogs. Copyright (c) 2010 by the American College of Veterinary Internal Medicine.
A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. [2010.12]
PURPOSE: This randomized, double-blind, controlled study examined whether lafutidine is superior to placebo and non-inferior to famotidine in terms of healing rates as assessed by endoscopy in Japanese patients with mild reflux esophagitis. Safety and improvement in symptoms of heartburn were also assessed... CONCLUSIONS: Lafutidine has a high endoscopic healing rate and improves symptoms of heartburn in patients with mild reflux esophagitis. Lafutidine is considered a promising treatment option for mild reflux esophagitis.
Clinical Trials Related to Pepcid Injection (Famotidine)
Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions [Completed]
The objective of this study was to compare the single-dose relative bioavailability of Reddy
Cheminor and Merck &Co, pepcid 40 mg famotidine tablets under fasting conditions.
A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED) [Completed]
A study in 24 healthy subjects to assess the bioequivalence of Famotidine/Antacid EZ Chew
tablet taken without water and with water compared to the Famotidine/Antacid tablet taken
with water. Subjects will be given a single dose of each treatment separated by 5 to 7 days.
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition [Completed]
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets,
USP 20 mg manufactured by OHM Laboratories with PepcidŽ AC Acid reducer famotidine tablets
20 mg (containing famotidine 20 mg) distributed by Johnson & Johnson. Merck Consumer
Pharmaceutical Co. Fort Washington, PA 19034 USA under fasting conditions.
A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets [Completed]
This study will determine whether the chewable tablet (CT) formulation of famotidine taken
with and without water is bioequivalent to the film coated tablet (FCT) formulation.
Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion [Completed]
Low-dose aspirin can prevent cerebral and cardiovascular accidents in individuals with
symptomatic atherothrombotic disease, but its use is frequently limited by gastrointestinal
The position of H2-receptor antagonists as a step-down therapy after healing of peptic ulcer
or erosions by proton pump inhibitor is unclear.
The objective of this randomized, double blinded control study was to compare the efficacy
of high-dose famotidine with pantoprazole in the prevention of recurrent dyspeptic or
complicated ulcer/ erosions in patients taking low-dose aspirin
Page last updated: 2011-12-09